Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
04/24/2017 04/25/2017 04/26/2017 04/27/2017 04/28/2017 Date
53.55(c) 53.94(c) 53.77(c) 55.67(c) 56.05(c) Last
9 783 267 9 321 100 9 453 860 15 317 773 8 196 789 Volume
+0.13% +0.73% -0.32% +3.53% +0.68% Change
More quotes
Financials ($)
Sales 2017 20 108 M
EBIT 2017 5 384 M
Net income 2017 4 664 M
Finance 2017 207 M
Yield 2017 2,82%
Sales 2018 20 737 M
EBIT 2018 5 694 M
Net income 2018 5 103 M
Finance 2018 1 097 M
Yield 2018 2,96%
P/E ratio 2017 20,00
P/E ratio 2018 18,60
EV / Sales2017 4,58x
EV / Sales2018 4,40x
Capitalization 92 339 M
More Financials
Company
Bristol-Myers Squibb Co. operates as a biopharmaceutical company, which engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products.It includes chemically-synthesized drugs or small molecules and products produced from biological... 
Sector
Pharmaceuticals
Calendar
05/02Shareholder meeting
More about the company
Surperformance© ratings of Bristol-Myers Squibb Co
Trading Rating : Investor Rating :
More Ratings
Latest news on BRISTOL-MYERS SQUIBB CO
04/29 BRISTOL MYERS SQUIBB : China FDA Approves Countrys First All-Oral Regimen for Ch..
04/28 BRISTOL MYERS SQUIBB : European Commission Approves Bristol-Myers Squibb’s..
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Dual-Drug Hepatitis C Treatm..
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis..
04/28 BRISTOL MYERS SQUIBB : China FDA Approves Country’s First All-Oral Regimen..
04/27 BRISTOL MYERS SQUIBB : and Nordic Bioscience Announce Collaboration for Fibrosis..
04/27 BRISTOL MYERS SQUIBB : Trademark Application for "PATIENT HUB" Filed by Bristol-..
04/27 BRISTOL MYERS SQUIBB : Investigators from Bristol-Myers Squibb Report New Data o..
04/27 Bristol-Myers Squibb Enters into Separate Agreements with Biogen and Roche to..
04/27 BRISTOL MYERS SQUIBB : Biogen Licenses Phase 2 Anti-Tau Antibody from Bristol-My..
More news
Sector news : Pharmaceuticals - NEC
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
04/27DJASTRAZENECA : Profit Drops on Decline in Blockbuster-Drug Revenue -- Update
04/27DJASTRAZENECA : Correction to AstraZeneca Profit Drops on Decline in Blockbuster-D..
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on BRISTOL-MYERS SQUIBB CO 
2016Attractive price levels
More Strategies
Latest Tweets
04/29Despite Worries, Bristol-Myers' Opdivo Keeps Racking Up Sales: Motley Fool  
04/295 Things Bristol-Myers Squibb's Management Wants You to Know  
04/29Bristol-Myers Squibb Co $BMY Shares Bought by Koshinski Asset Management Inc... 
04/29SOME OF TODAY'S OPENING LINES .. $AMZN $T $MDXG $FB $CAG $AXP $M $BIDU $LL $..
2
04/28$BMY: Bristol-Myers: EC approves Opdivo for monotherapy for the treatment of .. 
More tweets
Qtime:106
News from SeekingAlpha
04/28 SNIPPETS ROUNDUP : Sanofi Diabetes Disappointment, And Amgen Pullback Signals CG..
04/28 EC OKs use of Bristol-Myers' Opdivo to treat head and neck cancer
04/28 Is Bristol-Meyers Squibb A Good Long-Term Pick?
04/28 Nucor Is The Best Steel Stock - Cramer's Lightning Round (4/27/17)
04/28 WALL STREET BREAKFAST : Government Shutdown Looms
Advertisement
Chart BRISTOL-MYERS SQUIBB CO
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 57,0 $
Spread / Average Target 1,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB C..-4.09%92 339
JOHNSON & JOHNSON7.17%334 714
ROCHE HOLDING LTD.11.91%225 722
NOVARTIS AG3.78%202 360
PFIZER INC.4.43%201 998
MERCK & CO., INC.5.88%170 880
More Results